Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, said AstraZeneca
British-Swedish drugmaker AstraZeneca said on Monday its covid vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen. The British-Swedish drugmaker’s preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy. Earlier this week, Pfizer and Moderna had reported promising results from vaccine trials.
“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Pascal Soriot, Astra’s chief executive, said in a statement.
One dosing regimen shows vaccine efficacy of 90% when AZD1222 was given as half dose, followed by full dose at least a month apart. Second dosing regimen shows 62% efficacy when given two full doses at least a month apart. Combined analysis has average efficacy of 70%, said AstraZeneca
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, said AstraZeneca.
According to Oxford, COVID-19 vaccine is 70.4% effective, tests on two-dose regimens show it could be 90%, according to interim data.
